Skip to main content
. 2020 Oct 13;9(20):e017208. doi: 10.1161/JAHA.120.017208

Figure 3. Trends in evidence‐based pharmacotherapies for ST‐segment–elevation myocardial infarction (STEMI), presented with 95% CIs.

Figure 3

During the study period, several landmark clinical trials of traditional and novel pharmacotherapies were published, along with major clinical practice guidelines and performance measures for the treatment of STEMI. We demonstrate steady increases in the administration of nonaspirin antiplatelet agents and antithrombotic agents in the emergency department.